print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST

University of Antwerp, Vaccine & Infectious Disease Institute

Tell your friend  | 

Universiteitsplein 1
BE-2610 Wilrijk
Belgium

Contact email:

Visit the website.

Brief presentation of the institution

Since 1994 our lab has a strong focus on the immunobiology of human dendritic cells and antigen-specific T cell activation both in models of viral infections, auto-immune disorders, transplantation and cancer. Electroporation has been our method of choice to modify and load dendritic cells and various other cells of the immune system with macromolecules such as DNA and mRNA. We patented the method the mRNA electroporation of dendritic cells (US patent #7547551). The lab is an integral part of the Vaccine and Infectious Disease Institute founded in 2007 in the Faculty of Medicine and Health Sciences of the University of Antwerp. Next to basic cellular immunology research, we have been performing cutting-edge translational and clinical research applying the knowledge gathered at the lab bench and translated them into clinical trials. We developed the first personalized cell-based therapeutic cancer vaccine based on mRNA-electroporated dendritic cells for leukemia patients. In order to be able to conduct such clinical cellular immunotherapy trials, the Center for Cellular Therapy and Regenerative Medicine was established in 2008 of which I was the scientific director until mid 2012.

Main Electroporation related topics

Our major EP-related work revolves around (m)RNA electroporation of various human and mouse immune-competent cells (dendritic cells, cancer cells, PBMC) to engage or induce immune effects for the development of next-generation therapeutic vaccines for cancer and infectious diseases. Currently we are searching partners to develop EP-based electronic devices for medical applications.
 

Main Electroporation related research techniques and equipment

Our lab is equipped with:

3 GenePulser Xcell devices (BIORAD) and 1 EasyJect electroporator (Eurogentech)

cell culture incubators, laminar flow chambers, cooled centrifuges, automated cell counter (Horiba), automated 96-well plate washer, ...

real-time PCR device

Mono- and multilaser analytical flow cytometry devices (FACScan, FACSArray, Partec Cyflow, FACSCanto2

Multilaser cell sorting device (FACSAria II)

AID ELispot reader

Spectrofluorometer/Luminometer/Absorbance reader (PerkinElmer VICTOR™)

3 class B clean rooms (cell vaccine production facility)

Research topics, techniques and equipment not related to Electroporation

Brief information on available facilites

L2 laboratory for human cell cultures
molecular biology lab
clean room facility (air quality A in C) for early phase cell-based clinical trials

Willingness to accept/host visiting researchers

Members:

  • Sébastien Anguille
    Email:

    Position: MD
  • Eva Lion
    Email:

    Position: postdoctoral researcher
  • Evelien Smits
    Email:

    Position: senior scientist

Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: